cmi_logo.png
[Latest] Global Hydrogen Generation Market Size/Share Worth USD 280.4 Billion by 2032 at a 8.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
February 27, 2024 14:30 ET | Custom Market Insights
Austin, TX, USA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hydrogen Generation Market Size, Trends and Insights By Source (Green Hydrogen,...
Whitelogolarge.jpg
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – IMRA, SAL, APEN, GRAY
December 28, 2022 15:41 ET | Monteverde & Associates PC
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SAL, VVNT, APEN, GRAY
December 14, 2022 16:00 ET | Monteverde & Associates PC
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Acquisition – GRAY, APEN, SAL, KNBE
December 07, 2022 16:27 ET | Monteverde & Associates PC
NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
GB nlogo.png
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
November 10, 2022 16:59 ET | Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on...
GB nlogo.png
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
August 11, 2022 07:30 ET | Graybug Vision, Inc.
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...
GB nlogo.png
Graybug to Present at the 2022 OIS Retina Innovation Summit
July 06, 2022 07:15 ET | Graybug Vision, Inc.
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
GB nlogo.png
Graybug Announces Review of Strategic Alternatives
June 28, 2022 07:15 ET | Graybug Vision, Inc.
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
GB nlogo.png
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
May 19, 2022 07:30 ET | Graybug Vision, Inc.
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
GB nlogo.png
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022 16:05 ET | Graybug Vision, Inc.
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...